Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

Cancer

Volumn 119, Issue 20, 2013, Pages 3687-3695

  Luke, Jason J ^a   Callahan, Margaret K ^b   Postow, Michael A ^b   Romano, Emanuela ^c   Ramaiya, Nikhil ^a   Bluth, Mark ^b   Giobbie Hurder, Anita ^a   Lawrence, Donald P ^d   Ibrahim, Nageatte ^a   Ott, Patrick A ^a   Flaherty, Keith T ^d   Sullivan, Ryan J ^d   Harding, James J ^b   D'Angelo, Sandra ^b   Dickson, Mark ^b   Schwartz, Gary K ^b   Chapman, Paul B ^b   Wolchok, Jedd D ^b   Hodi, F Stephen ^a   Carvajal, Richard D ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

absolute lymphocyte count; cytotoxic T lymphocyte associated protein 4; immunotherapy; ipilimumab; uveal melanoma

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG RESPONSE; EUROPE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; HYPOPHYSITIS; IMMUNOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE COUNT; MALE; METASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; PANCREATITIS; PERFORMANCE; PRIORITY JOURNAL; RADIODIAGNOSIS; RASH; RETROSPECTIVE STUDY; THYROIDITIS; TOXIC HEPATITIS; UNITED STATES; UVEA MELANOMA; UVEITIS; VISUAL IMPAIRMENT; WORLD HEALTH ORGANIZATION;

ABSOLUTE LYMPHOCYTE COUNT; CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4; IMMUNOTHERAPY; IPILIMUMAB; UVEAL MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; UNIVERSITIES; UVEAL NEOPLASMS;

EID: 84885172487     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28282     Document Type: Article

References (28)

1. Singh AD, Topham A,. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003; 110: 956-961. (Pubitemid 36560496)
2. Kujala E, Makitie T, Kivela T,. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44: 4651-4659. (Pubitemid 37315273)
3. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009; 457: 599-602.
4. Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de Klein A,. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer. 2009; 101: 813-815.
5. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB,. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005; 23: 8076-8080. (Pubitemid 46657410)
6. Salmon RJ, Levy C, Plancher C, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol. 1998; 24: 127-130. (Pubitemid 28205941)
7. Nathan F, Sato T, Hart E,. Response to combination chemotherapy of liver metastasis from chorhoidal melanoma compared with cutaneous melanoma [abstract]. Proc Am Soc Clin Oncol. 1994; 13: 1994.
8. Bhatia S, Moon J, Margolin KA, et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512 [serial online]. PLoS One. 2012; 7: e48787.
9. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the MD Anderson Cancer Center experience and prognostic factors. Cancer. 1995; 76: 1665-1670.
10. Albert DM, Ryan LM, Borden EC,. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol. 1996; 114: 107-108. (Pubitemid 26026209)
11. de Vries TJ, Trancikova D, Ruiter DJ, van Muijen GN,. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer. 1998; 78: 1156-1161. (Pubitemid 28479143)
12. Luyten GP, van der Spek CW, Brand I, et al. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines. Melanoma Res. 1998; 8: 11-16. (Pubitemid 28114296)
13. Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin-2. Br J Cancer. 2002; 87: 840-845. (Pubitemid 35252958)
14. Soni S, Lee DS, DiVito J Jr, et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol. 2002; 24: 488-491.
15. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
16. Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012; 61: 41-48.
17. Khattak MA, Fisher R, Hughes P, Gore M, Larkin J,. Ipilimumab activity in advanced uveal melanoma. Melanoma Res. 2013; 23: 79-81.
18. Lawrence D, McDermott D, Hamid O, et al. Treatment of patients (pts) with stage III or IV melanoma on an ipilimumab (Ipi) expanded access program (EAP): results for 3 mg/kg cohort [abstract]. Paper presented at: Society for Melanoma Research 2012 Congress; November 8-11, 2012; Los Angeles, California.
19. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412-7420.
20. Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013; 24: 1697-1703.
21. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010; 116: 1767-1775.
22. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010; 11: 155-164.
23. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15: 5591-5598.
24. Bedikian AY, Johnson MM, Warneke CL, et al. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol. 2008; 5: 201-207. (Pubitemid 351882419)
25. Carvajal R, Ambrosini G, Wolchok J, et al. Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma [abstract]. J Clin Oncol. 2012: 30 (suppl). Abstract 8598.
26. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13: 782-789.
27. Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011; 17: 6574-6581.
28. Ascierto PA, Marincola FM, Ribas A,. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application [serial online]. J Transl Med. 2011; 9: 196.